A Case of Duodenal Metastasis From Malignant Pleural Mesothelioma Diagnosed by Gastrointestinal Endoscopy Following Progressive Anemia During Salvage Chemotherapy.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-06-01 DOI:10.1111/1759-7714.70098

Naruhiko Ichiyama, Hiromichi Yamane, Takako Saitou, Masafumi Miura, Ayaka Mimura, Yoko Kosaka, Tatsuyuki Kawahara, Yasunari Nagasaki, Nobuaki Ochi, Hidekazu Nakanishi, Hideyo Fujiwara, Nagio Takigawa

{"title":"A Case of Duodenal Metastasis From Malignant Pleural Mesothelioma Diagnosed by Gastrointestinal Endoscopy Following Progressive Anemia During Salvage Chemotherapy.","authors":"Naruhiko Ichiyama, Hiromichi Yamane, Takako Saitou, Masafumi Miura, Ayaka Mimura, Yoko Kosaka, Tatsuyuki Kawahara, Yasunari Nagasaki, Nobuaki Ochi, Hidekazu Nakanishi, Hideyo Fujiwara, Nagio Takigawa","doi":"10.1111/1759-7714.70098","DOIUrl":null,"url":null,"abstract":"<p><p>Malignant pleural mesothelioma (MPM) primarily progresses through direct invasion into the lung and pleura and is a refractory tumor in which asbestos exposure is a major underlying factor in most cases. Hematogenous metastasis of MPM is not uncommon in advanced stages, and reports suggest that metastatic sites may impact prognosis. Gastrointestinal metastases, ranging from the stomach to the colon, have been sporadically observed, but metastases to the small intestine and duodenum are exceedingly rare. Here, we report a case in which duodenal metastasis of MPM was endoscopically identified during the patient's lifetime while undergoing salvage chemotherapy following treatment with an immune checkpoint inhibitor and cytotoxic chemotherapy. Given the rarity and clinical significance of such cases, we present this report with a review of the relevant literature.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70098"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141785/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Malignant pleural mesothelioma (MPM) primarily progresses through direct invasion into the lung and pleura and is a refractory tumor in which asbestos exposure is a major underlying factor in most cases. Hematogenous metastasis of MPM is not uncommon in advanced stages, and reports suggest that metastatic sites may impact prognosis. Gastrointestinal metastases, ranging from the stomach to the colon, have been sporadically observed, but metastases to the small intestine and duodenum are exceedingly rare. Here, we report a case in which duodenal metastasis of MPM was endoscopically identified during the patient's lifetime while undergoing salvage chemotherapy following treatment with an immune checkpoint inhibitor and cytotoxic chemotherapy. Given the rarity and clinical significance of such cases, we present this report with a review of the relevant literature.

Abstract Image

查看原文本刊更多论文

补救性化疗期间进行性贫血后经胃肠内镜诊断的恶性胸膜间皮瘤十二指肠转移1例。

恶性胸膜间皮瘤（MPM）主要通过直接侵入肺和胸膜进展，是一种难治性肿瘤，石棉暴露在大多数病例中是主要的潜在因素。MPM的血液转移在晚期并不罕见，报告显示转移部位可能影响预后。从胃到结肠的胃肠道转移偶见，但转移到小肠和十二指肠极为罕见。在这里，我们报告了一个病例，在患者一生中，在接受免疫检查点抑制剂和细胞毒性化疗后进行补救性化疗时，内镜下发现了MPM的十二指肠转移。鉴于此类病例的罕见性和临床意义，我们在此报告中回顾了相关文献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.